Previous 10 | Next 10 |
The first half of the year is over. And good riddance. The S&P 500 experienced its worst first half in more than 50 years. Most investors saw the values of their holdings plunge. But the stock market won't remain in the doldrums forever. Here are three growth stocks that co...
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2022 on Thursday, July 28, 2022, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss the company’s financial re...
Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its phase 2 pilot KEYNOTE-B36 study, conducted in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA. KEYNOTE-B36 is designed to evaluate the safety and effectiveness of Tumor Treat...
Shares of Novocure (NASDAQ: NVCR) were plunging 18.5% this week as of the market close on Thursday, according to data from S&P Global Market Intelligence . The company didn't report any news. So what's behind the steep decline? Novocure was a victim of the broader marke...
Steep stock declines are always painful for investors who own the falling stocks. However, such sell-offs can provide great buying opportunities. We asked three Motley Fool contributors to identify stocks that are down 50% or more that you can buy right now. Here's why they picked Gin...
Novocure (NASDAQ:NVCR) and Zai Lab (NASDAQ:ZLAB) said a mid-stage study of their investigational device for Tumor Treating Fields (TTFields) met its main goal in patients with gastric cancer. TTFields are electric fields that are believed to disrupt cancer cell division. The co...
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% Novocure (NASDAQ: NVCR), a global oncology company working to extend surviv...
Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass. and ST. HELIER, Jersey, June 03, ...
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to study the use of Tumor Treating Fields (TTFields) concomitant with MSD’s anti-PD-1 therapy KEYTRUDA ® ...
The spread of the “recession” meme is starting to reach a fever pitch (1). In this case, it could counterintuitively be a positive catalyst for the long duration side of the market – ie, the long-term growth bets that are still in their early innings, with big fireworks s...
News, Short Squeeze, Breakout and More Instantly...
2024-08-02 13:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 17:30:15 ET Image source: The Motley Fool. NovoCure (NASDAQ: NVCR) Q2 2024 Earnings Call Jul 25, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: NovoCure (NVCR) Q2 2024 Earnings Call Transcript
Quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, 2024 Positive results from Phase 3 METIS trial in brain metastases from non-small cell lung cancer presented at ASCO 2024 Novocure (NASDAQ: NVCR) today reported fi...